NCT05083481 2026-02-27
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
Astellas Pharma Inc
Phase 1/2 Recruiting
Clinical Trials
8 trialsNCT05067283 2026-02-12
KANDLELIT-001
Merck Sharp & Dohme LLC
Phase 1 Recruiting
NCT06480552 2026-02-05
An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1 Recruiting
NCT07215637 2026-02-02
Phase Ia/Ib Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors
Chong Kun Dang Pharmaceutical
Phase 1 Recruiting
NCT07231458 2026-01-16
A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies
Abalos Therapeutics GmbH
Phase 1 Recruiting
NCT04185883 2025-10-22
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
Amgen
Phase 1 Active not recruiting
NCT04074759 2025-01-23
FPT155-001
Five Prime Therapeutics, Inc.
Phase 1 Terminated
NCT04699643 2021-01-07
FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid Tumors
EverNov Medicines (Zhuhai Hengqin) Co., Ltd
Phase 1/2 Unknown